{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"5","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the first of progression, relapse or death from any cause. Per criteria from International Workshop to Standardize Criteria for NHL (Cheson, 1999), progression (for patients who have not responded) and relapse (for patients who responded) are defined as:\n\n1. Appearances of any new lesions/sites during or after therapy\n2. Increase of ≥50% in the SPD from nadir measurement of all involved dominant lymph nodes and liver/spleen nodules or unequivocal progression in any nonmeasurable disease or nondominant site\n3. Increase by ≥50% in greatest diameter from nadir measurement of any previously involved dominant node \\>1.0 cm in its short axis","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nsorafenib tosylate: Given orally","id":"OG000","title":"Treatment (Sorafenib)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Assessed after month 2 and month 6, then every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry, up to 3 years","title":"Progression-Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}